JPM
JPMorgan Chase & Co.
JPM's fundamentals are strong, but it looks expensive: trading at 14x earnings, above its usual 12x. Analysts expect earnings growth.
PSEC
Prospect Capital Corporation
There isn't enough reported data to score PSEC yet.
JPM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
JPM's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like JPM.
PSEC Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Stable | |
| N/A | |
| N/A |
PSEC's profitability is currently stable, but its revenue is weak. Free cash flow and net leverage aren't meaningful measures for financial services companies like PSEC.
JPM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.7x | $231 | -33% |
| Fair | 12x | $287 | -16% |
| Current | 14x | $343 | — |
| Forward | 14x | $343 | — |
| Expensive | 15x | $361 | +5.2% |
Historical ranges are pointers, not guarantees.
JPM's PE is in its expensive range at 14.4x. If earnings grow as analysts expect, today's price would be 13.7x next year's earnings.
PSEC PE Valuation
PSEC has no meaningful PE right now: it lost money over the past year.
JPM Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
JPM has the edge over PSEC on the outlook, with more favorable earnings and revenue expectations.
PSEC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong decline | |
| Decline | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect PSEC's earnings and revenue to decline, with profitability weakening.
JPM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $24.99 | +4.8% |
| Q3 2026 | $23.85 | +18% |
| Q2 2026 | $23.35 | +20% |
| Q1 2026 | $20.89 | +2.5% |
| Q4 2025 | $20.02 | +1.4% |
| Q3 2025 | $20.20 | +12% |
| Q2 2025 | $19.50 | +8.7% |
| Q1 2025 | $20.38 | +23% |
| Q4 2024 | $19.75 | +22% |
JPM has the stronger earnings trend. Trailing diluted EPS is up 18% for JPM versus PSEC down 505%.
PSEC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.32 | — |
| Q3 2025 | -$0.89 | -$0.67 |
| Q2 2025 | -$1.35 | -497% |
| Q1 2023 | -$0.51 | -124% |
| Q4 2022 | $0.14 | -94% |
| Q3 2022 | $0.62 | -76% |
| Q2 2022 | $1.41 | -44% |
| Q1 2022 | $2.14 | -7.8% |
| Q4 2021 | $2.39 | +103% |
PSEC lost $0.89 per share over the past year, a bigger loss than the year before.
JPM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $50.2B | +8.1% |
| Q2 2026 | $57.3B | +28% |
| Q1 2026 | $49.8B | +10% |
| Q4 2025 | $45.8B | +7.1% |
| Q3 2025 | $46.4B | +8.8% |
| Q2 2025 | $44.9B | -11% |
| Q1 2025 | $45.3B | +8.1% |
| Q4 2024 | $42.8B | +11% |
JPM has the stronger quarterly revenue trend. Revenue is up 8.1% for JPM versus down 104% for PSEC.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 40% | -0.2 points |
| Q2 2026 | 48% | +7.3 points |
| Q1 2026 | 41% | +0.5 points |
| Q4 2025 | 37% | -3.2 points |
| Q3 2025 | 40% | +0.6 points |
| Q2 2025 | 41% | -6 points |
| Q1 2025 | 41% | -0.6 points |
| Q4 2024 | 41% | +11 points |
JPM's operating margin was 40% last quarter, about level with the same quarter a year ago.
PSEC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2022 | $203.3M | -32% |
| Q4 2021 | $293.9M | -17% |
| Q3 2021 | $253.7M | +19% |
| Q2 2021 | $284.3M | +37% |
| Q4 2020 | $353.2M | +753% |
PSEC's revenue has slid since its 2020 peak: −$11M last quarter, down 104% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2022 | 81% | -1.9 points |
| Q4 2021 | 86% | -0.3 points |
| Q3 2021 | 84% | +4.6 points |
| Q2 2021 | 86% | +7.2 points |
| Q1 2021 | 83% | N/A |
| Q4 2020 | 87% | +114 points |
| Q3 2020 | 79% | N/A |
| Q2 2020 | 79% | N/A |
PSEC's operating margin was 81% last quarter, down 1.9 points from the same quarter a year ago.
JPM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $33.2B | +$78.4B |
| Q2 2026 | -$25.3B | -186% |
| Q1 2026 | -$211.8B | +$40.1B |
| Q4 2025 | $119.7B | -19% |
| Q3 2025 | -$45.2B | +$28.9B |
| Q2 2025 | $29.5B | -23% |
| Q1 2025 | -$251.8B | -$97.7B |
| Q4 2024 | $147.8B | +145% |
JPM's free cash flow was −$84.2B over the past year, against −$120B the year before. Free cash flow isn't a meaningful measure for financial services companies like JPM.
PSEC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $381.7M | +37% |
| Q2 2026 | -$43.9M | -$36.3M |
| Q1 2026 | $195.7M | +149% |
| Q4 2025 | $85.6M | -69% |
| Q3 2025 | $279M | +61% |
| Q2 2025 | -$7.6M | -106% |
| Q1 2025 | $78.6M | +$100.8M |
| Q4 2024 | $278.5M | +251% |
PSEC has the edge over JPM on cash generation, producing positive trailing cash flow while its opponent burns cash.
JPM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -11.2M shares |
| 1 year | -3.1% | -84.6M shares |
| 3 years | -8.5% | -249M shares |
| 5 years | -11% | -322M shares |
| Available history | -17% | -547M shares |
JPM has the edge over PSEC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.1B |
| Q2 2026 | $6.8B |
| Q1 2026 | $8.3B |
| Q4 2025 | $8.3B |
| Q3 2025 | $8.3B |
| Q2 2025 | $7.5B |
| Q1 2025 | $7.5B |
| Q4 2024 | $4.3B |
JPM spent $24.5B buying back its own shares over the past year, down 11% from the year before.
PSEC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -44% | -405M shares |
| 1 year | +18% | +81M shares |
| 3 years | -4.2% | -22.9M shares |
| 5 years | +37% | +143M shares |
| Available history | +43% | +157M shares |
PSEC has 524M diluted shares, up 18% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
JPM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.5x | Very low |
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.6x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.4x | Very low |
JPM's net debt is less than a year of its operating earnings (EBITDA). Net leverage isn't a meaningful measure for financial services companies like JPM.
PSEC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2022 | 4.7x | High |
| Q1 2022 | 2.9x | Moderate |
| Q4 2021 | 2.4x | Moderate |
| Q3 2021 | 2.0x | Moderate |
| Q2 2021 | 2.3x | Moderate |
| Q1 2021 | 2.3x | Moderate |
| Q4 2020 | 4.6x | High |
| Q3 2020 | 16.0x | High |
PSEC's net debt is about 4.7 years of its operating earnings (EBITDA), up from 2.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like PSEC.
JPM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.8 | Neutral |
| Stochastic | 31.5 | Neutral |
JPM's weekly RSI is 55 (neutral) and its Stochastic is 31 (neutral).
PSEC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.3 | Oversold |
| Stochastic | 13.6 | Oversold |
PSEC's weekly RSI is 26 (oversold) and its Stochastic is 14 (oversold).
JPM PE vs Financial Services Sector
| Metric | JPM | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 13x | 10% above |
| PE % | 76 | 63 | 13 pts above |
JPM is trading at 14x earnings, a 10% premium to the Financial Services sector's median of 13x.
PSEC PE vs Financial Services Sector
| Metric | PSEC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
PSEC has no meaningful PE right now: it lost money over the past year.
JPM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $336.8 | 1.8% above |
| 20 week MA | $345.3 | 0.7% below |
| 50 week MA | $323.2 | 6.1% above |
| 100 week MA | $298.9 | 15% above |
| 200 week MA | $236.6 | 45% above |
JPM has the edge over PSEC on trend strength, trading above more of its moving averages.
PSEC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.68 | 16% below |
| 20 week MA | $2.01 | 30% below |
| 50 week MA | $2.36 | 40% below |
| 100 week MA | $2.91 | 52% below |
| 200 week MA | $4.40 | 68% below |
PSEC is in a downtrend: it's below all five of its weekly moving averages, and 68% below its 200-week average.
JPM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $139.1 | $124.5 | -11% |
| 2021 | $124.5 | $157.3 | +26% |
| 2022 | $157.3 | $131.3 | -17% |
| 2023 | $131.3 | $170.1 | +30% |
| 2024 | $170.1 | $241.2 | +42% |
| 2025 | $241.2 | $327.9 | +36% |
| 2026 YTD | $327.9 | $342.8 | +4.5% |
JPM has the edge over PSEC on returns for 2026, with the stronger performance.
PSEC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.51 | $5.46 | -16% |
| 2021 | $5.46 | $8.43 | +54% |
| 2022 | $8.43 | $7.16 | -15% |
| 2023 | $7.16 | $5.99 | -16% |
| 2024 | $5.99 | $4.26 | -29% |
| 2025 | $4.26 | $2.51 | -41% |
| 2026 YTD | $2.51 | $1.41 | -44% |
PSEC has finished four years in a row lower, and it's down 44% so far in 2026.